I. Introduction

Allergic rhinitis
• More commonly known as 'hayfever', but also including hypersensitivity to house dust mites
• Not restricted to nasal complaints, but also potential other symptoms: eyes, lungs ("allergic asthma"), chronic fatigue & concentration problems, sleeping disturbance
• Approx. 20% of Europeans affected, more in urban areas
• Significant expense, both prescription and OTC drugs which suppress symptoms.
• Also: preventive "vaccination" using allergen immunotherpy; well established and part of Dutch basic benefits package
Allergen immunotherapy
• Basic idea: desensitize immune system for 3 yrs by administering extract(s) of the offending allergen(s) 
Analysis of persistence
Analysis of compliance & costs
• Of 1126 fully persistent patients (both groups), 38.4% were noncompliant, being on average 1.2 times late at the pharmacy.
• Total and per patient direct pharmaceutical costs rise as treatment progresses (undiscounted) 
NONCOMPLIANCE & (COSTS OF) NONPERSISTENCE
IV. Discussion
• Compliance seems decent, but only measured in persistent patients. In line with literature on the subject.
• Only about 6% of SLIT users and 21% of SCIT users achieve a minimum total treatment duration of 3 yrs, though hazard rate of RoA (SCIT vs. SLIT) itself hard to predict due to violation of PHA.
• Though easy to use, daily SLIT treatment seems hard, monthly SCIT treatment preferred, and, in these long and intensive treatments, GP care is preferred over specialist outpatient care
• Costs of nonpersistence are impressive, but are not completely forgone: some long-term effects on symptoms may certainly be expected, but discounting is problematic.
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